About Ironwood Pharma
Ironwood Pharma is a company based in Cambridge (United States) founded in 1998. Ironwood Pharma has raised $206.25 million across 8 funding rounds from investors including Morgan Stanley, Ridgeback Capital Management and Invus. The company has 253 employees as of December 31, 2024. Ironwood Pharma has completed 1 acquisition, including VectivBio. Ironwood Pharma offers products and services including LINZESS. Ironwood Pharma operates in a competitive market with competitors including RedHill Biopharma, Alcresta, Seed, Ardelyx and Norgine, among others.
- Headquarter Cambridge, United States
- Employees 253 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ironwood Pharmaceuticals, Inc.
-
Annual Revenue
$351.41 M (USD)-20.63as on Dec 31, 2024
-
Net Profit
$880 K (USD)0as on Dec 31, 2024
-
EBITDA
$97.73 M (USD)-53.6as on Dec 31, 2024
-
Total Equity Funding
$206.25 M (USD)
in 8 rounds
-
Latest Funding Round
$341 M (USD), Post-IPO
Aug 12, 2019
-
Investors
Morgan Stanley
& 8 more
-
Employee Count
253
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ironwood Pharma
Ironwood Pharma is a publicly listed company on the NASDAQ with ticker symbol IRWD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ironwood Pharma
Ironwood Pharma offers a comprehensive portfolio of products and services, including LINZESS.
Medication for treating gastrointestinal diseases and symptoms.
People of Ironwood Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Ironwood Pharma
Ironwood Pharma has successfully raised a total of $206.25M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $341 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ironwood Pharma
Ironwood Pharma has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Ridgeback Capital Management and Invus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked |
Investor details for Ironwood Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ironwood Pharma
Ironwood Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include VectivBio.
Investment portfolio details for Ironwood Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Transformative therapeutics for rare diseases are developed.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Ironwood Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Ironwood Pharma
Detailed financials for Ironwood Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ironwood Pharma Comparisons
Peer comparison for Ironwood Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ironwood Pharma
Ironwood Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RedHill Biopharma, Alcresta, Seed, Ardelyx and Norgine, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
|
Detailed competitors of Ironwood Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ironwood Pharma
Complete news archive for Ironwood Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ironwood Pharma
Ironwood Pharma was founded in 1998 and raised its 1st funding round 4 years after it was founded.
Ironwood Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Thomas Mccourt is the current CEO of Ironwood Pharma.
Ironwood Pharma is a funded company, having raised a total of $206.25M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Ironwood Pharma is 253.
Annual revenue of Ironwood Pharma is $351.41M as on Dec 31, 2024.
Ironwood Pharma was founded in 1998 in Cambridge, United States, within the pharmaceutical sector. Focus is placed on developing treatments for gastrointestinal conditions. Linaclotide, the lead product, acts as a guanylate cyclase-C agonist and is approved for irritable bowel syndrome with constipation as well as chronic idiopathic constipation. Provisions for pediatric gastrointestinal diseases are also included in the portfolio.
Ironwood Pharma's top competitors include Ardelyx, RedHill Biopharma and Seed.
Ironwood Pharma offers LINZESS.
Yes, Ironwood Pharma is publicly traded on NASDAQ under the ticker symbol IRWD.
Ironwood Pharma has made 1 acquisition, including VectivBio.
Ironwood Pharma has 9 investors. Key investors include Morgan Stanley, Ridgeback Capital Management, Invus, EDBI, and Venrock.
The ticker symbol of Ironwood Pharma is IRWD on NASDAQ.